106 related articles for article (PubMed ID: 6674493)
21. Polymeric alkenoxy amino acid surfactants: II. Chiral separations of beta-blockers with multiple stereogenic centers.
Rizvi SA; Akbay C; Shamsi SA
Electrophoresis; 2004 Mar; 25(6):853-60. PubMed ID: 15004846
[TBL] [Abstract][Full Text] [Related]
22. [Labetalol (Trandate). an antihypertensive agent with both alpha and beta receptor blockading effects].
Rasmussen S; Andreasen PB
Ugeskr Laeger; 1980 Mar; 142(13):839-41. PubMed ID: 6102812
[No Abstract] [Full Text] [Related]
23. High-performance liquid chromatographic assay for labetalol in human plasma using a PRP-1 column and fluorometric detection.
Alton KB; Leitz F; Bariletto S; Jaworsky L; Desrivieres D; Patrick J
J Chromatogr; 1984 Nov; 311(2):319-28. PubMed ID: 6520179
[TBL] [Abstract][Full Text] [Related]
24. Paired-ion chromatography and high performance liquid chromatography of labetalol in feeds.
Townley ER; Ross B
J Assoc Off Anal Chem; 1980 Nov; 63(6):1262-5. PubMed ID: 7451388
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of hypertension by labetalol (author's transl)].
Sternon J; Melot C; Contu E
Rev Med Brux; 1980 Nov; 1(9):615-21. PubMed ID: 7455430
[No Abstract] [Full Text] [Related]
26. Metabolism of pronethalol in the rat, the guinea pig and the mouse.
Stillwell WG; Horning MG
Res Commun Chem Pathol Pharmacol; 1974 Dec; 9(4):601-19. PubMed ID: 4156416
[No Abstract] [Full Text] [Related]
27. Pharmacological basis for antihypertensive effects of intravenous labetalol.
Richards DA; Prichard BN; Boakes AJ; Tuckman J; Knight EJ
Br Heart J; 1977 Jan; 39(1):99-106. PubMed ID: 12778
[TBL] [Abstract][Full Text] [Related]
28. Letter: Intravenous labetalol in severe hypertension.
Rosei EA; Trust PM; Brown JJ; Lever AF; Robertson JI
Lancet; 1975 Nov; 2(7944):1093-4. PubMed ID: 53581
[No Abstract] [Full Text] [Related]
29. Labetalol: an alpha- and beta-adrenergic receptor blocker.
Pepper GA
Nurse Pract; 1985 Jul; 10(7):39-40, 43, 48. PubMed ID: 3855235
[No Abstract] [Full Text] [Related]
30. [Labetalol and guanfacine in the treatment of arterial hypertension in patients with chronic renal failure].
Lifshits NL; Ermolenko VM; Rozhdestvenskaia TM; Tatsievskiĭ VA; Panasiuk VV
Ter Arkh; 1984; 56(7):66-9. PubMed ID: 6385325
[No Abstract] [Full Text] [Related]
31. Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.
Bellamy GR; Hunyor SN; Roffe D; Massang J
Br J Clin Pharmacol; 1983 Jul; 16(1):9-16. PubMed ID: 6882628
[TBL] [Abstract][Full Text] [Related]
32. GLC assay of sorbitol as cyclic n-butylboronate.
Rabinowitz MP; Reisberg P; Bodin JI
J Pharm Sci; 1974 Oct; 63(10):1601-4. PubMed ID: 4436796
[No Abstract] [Full Text] [Related]
33. Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.
West MJ; Wing LM; Mulligan J; Walkley J; Grygiel JJ; Graham JR; Chalmers JP
Med J Aust; 1980 Mar; 1(5):224-5. PubMed ID: 6990215
[TBL] [Abstract][Full Text] [Related]
34. [Hypertensive emergencies: clinical evaluation of the use of a new drug: labetalol hydrochloride].
Rossano P; Saffiotti O; Mayer MC; Blasich M; Rossano G; Bellotti P
Minerva Cardioangiol; 1980 May; 28(5):309-14. PubMed ID: 6111048
[No Abstract] [Full Text] [Related]
35. Stereospecific gas chromatographic/mass spectrometric assay of the chiral labetalol metabolite 3-amino-1-phenylbutane.
Changchit A; Gal J; Zirrolli JA
Biol Mass Spectrom; 1991 Dec; 20(12):751-8. PubMed ID: 1812984
[TBL] [Abstract][Full Text] [Related]
36. Labetalol in hypertension.
Lancet; 1977 May; 1(8022):1147-8. PubMed ID: 68239
[No Abstract] [Full Text] [Related]
37. Closing remarks: current status of labetalol.
Dollery CT
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):823-4. PubMed ID: 10954
[No Abstract] [Full Text] [Related]
38. Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol.
Andersson O; Berglund G; Hansson L
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):757-61. PubMed ID: 1032990
[TBL] [Abstract][Full Text] [Related]
39. Labetalol: potent antihypertensive agent that blocks both alpha- and beta-adrenergic receptors.
Milne BJ; Logan AG
Can Med Assoc J; 1980 Nov; 123(10):1013-6. PubMed ID: 6256045
[TBL] [Abstract][Full Text] [Related]
40. Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy.
Sanders GL; Routledge PA; Ward A; Davies DM; Rawlins MD
Br J Clin Pharmacol; 1979; 8(Suppl 2):153S-155S. PubMed ID: 526396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
